UK biotech Epsilogen has acquired US-based antibody developer TigaTx in a deal that collates work from the two companies’ ...

An asthma medication called omalizumab can stop your body from having an allergic response to pollen and even food.

However, IgGs have not been effective against ovarian cancer. Researchers at King's are the first in the world to develop a ...

Study reveals how a new IgE antibody therapy reactivates immune cells, offering a promising approach to fighting ovarian ...

The guidelines for treating seasonal allergic rhinitis with medications suggest that you use intranasal corticosteroids ...

Epsilogen rose to prominence a few years ago by becoming the first biotech to start clinical testing of an antibody therapy for cancer based on immunoglobulin E (IgE), a departure from most ...

Class switching to IgE and affinity maturation of the antibodies occur in mucosal tissues, and this may limit the ability of IgE antibodies to mediate systemic anaphylaxis. Various mechanisms ...

an anti-Folate Receptorα IgE antibody, currently in a Phase Ib Proof of Concept trial in platinum-resistant ovarian cancer. Data from a Phase I trial found it to be safe and well tolerated with ...

IgE, which is a specific class of monoclonal antibody, triggers reactions after people are exposed to allergens, Grossman said. “Individuals with AGS have IgE specific to various animal proteins ...

Researchers at King's are the first in the world to develop a treatment from a different type of antibody, called IgE. IgE has important roles in triggering the immune response during an allergic ...